Globally, the incidence of anaplastic thyroid cancer (ATC) has followed a stable trend. However, over the past decade, we have observed a marked rise in the number of cases in the North Yorkshire region of the United Kingdom. Our study aimed to explore the incidence, demographics, and geographical distribution of ATC in this region over a 12-year period. We retrieved the clinical records of all patients with ATC in our centre from 2010 to 2022 and determined the incidence, demographics, and geographical spread of the data. 20 patients were diagnosed with ATC within the data collection period, with an average annual incidence of 14 per 10,000,000 of the entire North Yorkshire population (35 per 10,000,000 age-adjusted incidence rate). There was a clustering of data around the North Yorkshire region centre. The incidence of ATC in North Yorkshire was geometrically higher than the national average of 1.7 per 10,000,000. The geographical clustering around the region's centre was likely explained by its higher population density.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577495PMC
http://dx.doi.org/10.7759/cureus.72006DOI Listing

Publication Analysis

Top Keywords

north yorkshire
20
yorkshire region
12
incidence anaplastic
8
anaplastic thyroid
8
thyroid cancer
8
incidence demographics
8
demographics geographical
8
incidence
7
north
5
yorkshire
5

Similar Publications

Introduction: Tobacco smoking remains a leading cause of ill-health, premature mortality and a driver of health inequalities. To support smokers in England, a comprehensive approach to treating tobacco dependence is being implemented. This includes offering support to all people admitted to hospitals, as well as women and pregnant people within NHS settings.

View Article and Find Full Text PDF

Background: The NHS Jewish BRCA Testing Programme is offering germline and genetic testing to people with ≥1 Jewish grandparent. Who have an increased likelihood of having an Ashkenazi Jewish (AJ) founder germline pathogenic variant (gPV) compared with the general population.Testing is offered via a self-referral, home-based saliva sampling pathway, supported by a genetic counsellor telephone helpline.

View Article and Find Full Text PDF

ALSUntangled #77: Psilocybin.

Amyotroph Lateral Scler Frontotemporal Degener

December 2024

Department of Neurology, Duke University, Durham, NC, USA.

ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation.

View Article and Find Full Text PDF

Categorization systems for tick-borne encephalitis virus (TBEV) infection lack consistency in classifying disease severity. To evaluate the need for a standard, consensus-based categorisation system for TBEV infection across subtypes, we gathered an expert panel of clinicians and scientists with diverse expertise in TBEV infection. Consensus was sought using the Delphi technique, which consisted of 2 web-based survey questionnaires and a final, virtual, consensus-building exercise.

View Article and Find Full Text PDF

Background: Identifying influences on disability accumulation in multiple sclerosis (MS), including modifiable factors other than the core features of disease itself, is vital for clinical care, but has often relied on instruments with acknowledged psychometric shortcomings. We model MS disability using the WHO Disability Assessment Schedule (WHODAS) 2.0, a validated measure based on the WHO's biopsychosocial model and sensitive to the breadth of disability-related domains important to people, to investigate the factors associated with its trajectory after diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!